Effect and process evaluation of an intervention program on physical activity and sedentary behavior in castrate resistant prostate cancer patients Ghent University
Recent drug improvement (e.g. abiraterone or enzalutamide) for castration resistant prostate
cancer (CRPC) patients has improved survival. As treatment strategies improve and patients live
longer, patients must cope with their treatment-induced adverse effects. Improving levels of
physical activity (PA) and less amounts of sitting time (e.g. sedentary behavior, SB) could have a
positive impact on ...